Acetylcholine

Overview

A neurotransmitter. Acetylcholine in vertebrates is the major transmitter at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. It is generally not used as an administered drug because it is broken down very rapidly by cholinesterases, but it is useful in some ophthalmological applications.

Indication

Used to obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy and other anterior segment surgery where rapid miosis may be required.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Early Neurovascular Adaptations in Aging Women	2024/07/25	NCT06520982	Early Phase 1	Recruiting	University of Missouri-Columbia
Comparing Approaches to Assess Nitric Oxide-dependent Cutaneous Vasodilation	2024/07/15	NCT06499844	Early Phase 1	Not yet recruiting	University of Iowa
Investigation of Endothelium-dependent Vasodilation in Human Gingiva	2024/06/12	NCT06454084	Not Applicable	Active, not recruiting	Semmelweis University
Role of Endothelial Function in SCI CVD Risk	2024/06/05	NCT06443151	N/A	Recruiting	Craig Hospital
Estrogen and Microvascular Function	2023/09/21	NCT06043310	N/A	Active, not recruiting	Medical College of Wisconsin
Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes	2023/07/14	NCT05946785	Early Phase 1	Recruiting	Anna Stanhewicz, PhD
Role of NADPH Oxidase in Microvascular Dysfunction Following GDM	2023/07/14	NCT05946798	Early Phase 1	Recruiting	Anna Stanhewicz, PhD
Prenatal Aspirin and Postpartum Vascular Function	2022/12/16	NCT05653973	Early Phase 1	Recruiting	Anna Stanhewicz, PhD
Hot Flashes and Neurovascular Function in Women	2022/01/18	NCT05193968	Not Applicable	Recruiting	Mayo Clinic
Endothelium Dependent and Non-dependent Vasodilatation in Human Gingiva	2021/06/09	NCT04918563	Not Applicable	Completed	Semmelweis University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
MIOCHOL-E INTRAOCULAR SOLUTION	Novartis Pharma Stein AG	SIN09252P	INJECTION	20 mg/2 ml	3/18/1997

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
MIOCHOL-E acetylcholine chloride 20mg/2mL powder for solution for intraocular irrigation	118510	Bausch & Lomb Australia Pty Ltd	Medicine	A	8/31/2005

Related News

Health Canada Approves Expanded Dosing and Pediatric Indication for FIRDAPSE in Lambert-Eaton Myasthenic Syndrome

25 days ago

Health Canada has approved Kye Pharmaceuticals' supplemental new drug submission for FIRDAPSE (amifampridine), allowing some patients with Lambert-Eaton myasthenic syndrome to benefit from an increased maximum daily dose of up to 100mg.

Japan Approves Luye Pharma's Twice-Weekly Rivastigmine Patch for Alzheimer's Disease

3 months ago

Japan's Ministry of Health, Labour and Welfare has approved Luye Pharma's innovative Rivastigmine Twice Weekly Transdermal Patch (Rivaluen® LA Patch) for mild to moderate Alzheimer's disease, marking the first extended-release rivastigmine transdermal formulation in the country.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access